Non-sufficient cell cycle control as possible clue for the resistance of human malignant glioma cells to clinically relevant treatment conditions

Amino Acids

Volumn 32, Issue 3, 2007, Pages 373-379

  Trog, D ^a   Moenkemann, H ^a   Breipohl, W ^a   Schueller, H ^a   Schild, H ^a   Golubnitschaja, O ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Cell cycle control; Comet assay; Differential gene expression; DNA damage; Glioma therapy; Stress

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1; PROTEIN P53; TEMOZOLOMIDE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL PROLIFERATION; COMET ASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DAMAGE; DNA DETERMINATION; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRESS; SURVIVAL RATE; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; COMET ASSAY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DACARBAZINE; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; GLIOMA; HUMANS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34147127434     PISSN: 09394451     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00726-006-0456-1     Document Type: Article

References (30)

1. I Ader C Delmas J Bonnet P Rochaix G Favre C Toulas E Cohen-Jonathan-Moyal 2003 Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts Oncogene 22 8861 8869
2. M Bower ES Newlands NM Bleehen M Brada RJ Begent H Calvert I Colquhoun P Lewis MH Brampton 1997 Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma Cancer Chemother Pharmacol 40 484 488
3. BD Chang K Watanabe EV Broude J Fang JC Poole TV Kalinichenko IB Roninson 2000 Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases Proc Natl Acad Sci USA 97 4291 4296
4. J Chen T Willingham M Shuford D Bruce E Rushing Y Smith PD Nisen 1996 Effects of ectopic overexpression of p21(WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumor cells Oncogene 13 1395 1403
5. BJ Denny RT Wheelhouse MF Stevens LL Tsang JA Slack 1994 NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA Biochemistry 33 9045 9051
6. O Golubnitschaja H Moenkemann K Kim MS Mozaffari 2003 DNA damage and expression of checkpoint genes p21(WAF1/CIP1) and 14-3-3 sigma in taurine-deficient cardiomyocytes Biochem Pharmacol 66 511 517
7. O Golubnitschaja-Labudova R Liu C Decker P Zhu IO Haefliger J Flammer 2000 Altered gene expression in lymphocytes of patients with normal-tension glaucoma Curr Eye Res 21 867 876
8. B Hegedus J Zach A Czirok J Lovey T Vicsek 2004 Irradiation and Taxol treatment result in non-monotonous, dose-dependent changes in the motility of glioblastoma cells J Neurooncol 67 147 157
9. 6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells J Neurochem 96 766 776
10. Y Hirose MS Berger RO Pieper 2001 p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells Cancer Res 61 1957 1963
11. H Horiguchi T Sano T Hirose 2001 TP53 deleted cells in de novo glioblastomas using fluorescence in situ hybridization Pathol Int 51 187 192
12. T Kokunai I Izawa N Tamaki 1998 Overexpression of p21WAF1/CIP1 induces cell differentiation and growth inhibition in a human glioma cell line Int J Cancer 75 643 648
13. S Kominsky HM Johnson G Bryan T Tanabe AC Hobeika PS Subramaniam B Torres 1998 IFNgamma inhibition of cell growth in glioblastomas correlates with increased levels of the cyclin dependent kinase inhibitor p21WAF1/CIP1 Oncogene 17 2973 2979
14. M Lemay KA Wood 1999 Detection of DNA damage and identification of UV-induced photoproducts using the CometAssay kit Biotechniques 27 846 851
15. RS Malyapa C Bi EW Ahern Roti JL Roti 1998 Detection of DNA damage by the alkaline comet assay after exposure to low-dose gamma radiation Radiat Res 149 396 400
16. H Moenkemann J Flammer K Wunderlich W Breipohl HH Schild O Golubnitschaja 2005 Increased DNA breaks and up-regulation of both G(1) and G(2) checkpoint genes p21(WAF1/CIP1) and 14-3-3 sigma in circulating leukocytes of glaucoma patients and vasospastic individuals Amino Acids 28 199 205
17. M Muller 2000 Transcriptional control of hepatocanalicular transporter gene expression Semin Liver Dis 20 323 337
18. CL Nutt M Noble AF Chambers JG Cairncross 2000 Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy Cancer Res 60 4812 4818
19. H Ohgaki P Dessen B Jourde S Horstmann T Nishikawa PL Di Patre C Burkhard D Schuler NM Probst-Hensch PC Maiorka N Baeza P Pisani Y Yonekawa MG Yaşargil UM Lutolf P Kleihues 2004 Genetic pathways to glioblastoma: a population-based study Cancer Res 64 6892 6899
20. D Osoba M Brada WK Yung M Prados 2000 Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme J Clin Oncol 18 1481 1491
21. O Ostling KJ Johanson 1984 Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells Biochem Biophys Res Commun 123 291 298
22. F Paulsen W Hoffmann G Becker C Belka M Weinmann J Classen RD Kortmann M Bamberg 1999 Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide J Cancer Res Clin Oncol 125 411 418
23. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn K Belanger AA Brandes C Marosi U Bogdahn J Curschmann RC Janzer SK Ludwin T Gorlia A Allgeier D Lacombe JG Cairncross E Eisenhauer RO Mirimanoff 2005 European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996
24. L Tentori I Portarena F Torino M Scerrati P Navarra G Graziani 2002 Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G2/M cell accumulation induced by temozolomide in malignant glioma cells Glia 40 44 54
25. D Trog H Moenkemann N Haertel H Schuller O Golubnitschaja 2005 Expression of ABC-1 transporter is elevated in human glioma cells under irradiation and temozolomide treatment Amino Acids 28 213 219
26. D Trog M Fountoulakis A Friedlein O Golubnitschaja 2006a Is current therapy of malignant gliomas beneficial for patients? Proteomics evidence of shifts in glioma cells expression patterns under clinically relevant treatment conditions Proteomics 6 2924 2930
27. D Trog K Yeghiazaryan M Fountoulakis A Friedlein H Moenkemann N Haertel H Schueller W Breipohl H Schild D Leppert O Golubnitschaja 2006b Pro-invasive gene regulating effect of irradiation and combined temozolomide-radiation treatment on surviving human malignant glioma cells Eur J Pharmacol 542 8 15
28. 6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU Br J Cancer 73 1049 1052
29. C Wild-Bode M Weller A Rimner J Dichgans W Wick 2001 Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma Cancer Res 61 2744 2750
30. WK Yung MD Prados R Yaya-Tur SS Rosenfeld M Brada HS Friedman R Albright J Olson SM Chang AM O'Neill AH Friedman J Bruner N Yue M Dugan S Zaknoen VA Levin 1999 Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group J Clin Oncol 17 2762 2771